Pharma BD Deal Intelligence
Schering bought a Finnish radiopharma specialist in 2002 to build out its diagnostics-therapy strategy, then divested it back to management within about two years — and exited the entire radiopharmaceuticals category by 2006, making this a strategy reversal rather than a value-creating deal.
Full analysis, sources & comparables →Schering AG acquired all shares of MAP Medical Technologies Oy through its Finnish subsidiary Leiras Oy; MAP was the leading radiopharmaceutical company in…
Schering AG's diagnostic/radiopharmaceuticals unit generates 30 percent of the company's revenue; 'We are developing products that use these targeting…
MAP Medical Technologies Oy, founded in 1991, is an independent Finnish company focused on developing and manufacturing radiopharmaceuticals — Curium has…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Schering AG, through its Finnish subsidiary Leiras Oy, acquired all outstanding shares of privately held Helsinki radiopharmaceutical company MAP Medical Technologies Oy (announced 10 July 2002), then the leading radiopharmaceutical firm in Finland with cancer and neurodegenerative-disease diagnostic products. The acquisition expanded Schering's diagnostic-imaging/radiopharmaceutical portfolio. Financial terms were not disclosed.
Schering bought a Finnish radiopharma specialist in 2002 to build out its diagnostics-therapy strategy, then divested it back to management within about two years — and exited the entire radiopharmaceuticals category by 2006, making this a strategy reversal rather than a value-creating deal.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Schering AG / MAP Medical Technologies Oy (this deal) | 2002 | — | 26 |
| Schering AG / Collateral Therapeutics Inc. | 2002 | $140M | 9 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
← Browse all deals · How we score deals
More: 2002 deals · Neurology deals